ValGenesis secures $16m financing to accelerate global expansion, AI-driven innovation

ValGenesis, a global player in digital validation lifecycle management and backed by investment funds managed by Morgan Stanley Expansion Capital, has secured a strategic financing of $16 million from the Innovation Banking Group at Bridge Bank. The Innovation Banking Group specializes in serving high-growth life sciences, technology, and innovation companies.

This financing will help fuel ValGenesis’ global expansion plans and accelerate product innovation, particularly in artificial intelligence-powered validation solutions. The funding comes at a pivotal moment for ValGenesis, which recently launched a groundbreaking AI-assisted validation program and continues to set new industry standards for digitalizing validation.

Siva Samy, CEO and Chief Product Strategist, ValGenesis: ''We believe this financing reflects the strong confidence that Bridge Bank and Morgan Stanley Expansion Capital have in our vision, innovation, and execution. Our AI-assisted validation platform, backed by a growing number of issued patents, is transforming how life sciences companies manage compliance and accelerate time to market. This capital allows us to rapidly scale our AI offerings and deepen our global presence.''

The new funds will also support strategic hiring, regional partner expansion, and customer success initiatives across North America, Europe, and Asia-Pacific, enabling ValGenesis to meet the surging demand for digital validation solutions in regulated industries.

Peter Haman, Market Director, Bridge Bank Innovation Banking Group: ''Bridge Bank is honored to serve as the banking partner for ValGenesis, an innovation-driven company that is leading the way in digitalizing validation in life sciences. We are confident that our support will enable ValGenesis to accelerate its growth trajectory and enhance its market presence while continuing to provide exceptional value to its customers.''

ValGenesis is trusted by pharmaceutical, biotech, and medical device organizations to digitize and automate their validation lifecycle processes, ensuring compliance, traceability, and efficiency at scale. The company recently launched ValGenesis Smart GxP, the first AI-enabled platform purpose-built to unify validation and process lifecycle management across life sciences organizations.

Melissa Daniels, Managing Director, Morgan Stanley Expansion Capital: ''ValGenesis has consistently delivered impressive double digit growth year over year and carved out clear market leadership in bringing innovative digital validation solutions to life sciences. We are confident that this new financing positions the company to accelerate its global expansion, deepen product innovation, and redefine industry best practices.''

www.valgenesis.com

Follow Marketing Report on LinkedIn